The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer

Anna Di Benedetto, Marcella Mottolese, Francesca Sperati, Cristiana Ercolani, Luigi Di Lauro, Laura Pizzuti, Patrizia Vici, Irene Terrenato, Isabella Sperduti, Abeer M. Shaaban, Sreekumar Sundara-Rajan, Maddalena Barba, Valerie Speirs, Ruggero De Maria, Marcello Maugeri-Saccà

Research output: Contribution to journalArticle

Abstract

Male breast cancer (MBC) is a rare disease and its biology is poorly understood. Deregulated Hippo pathway promotes oncogenic functions in female breast cancer. We herein investigated the expression of the Hippo transducers TAZ/YAP and their target CTGF in MBC. Tissue microarrays containing samples from 255 MBC patients were immunostained for TAZ, YAP and CTGF. One hundred and twenty-nine patients were considered eligible. The Pearson's Chi-squared test of independence was used to test the association between categorical variables. The correlation between TAZ, YAP and CTGF was assessed with the Pearson's correlation coefficient. The Kaplan- Meier method and the log-rank test were used for estimating and comparing survival curves. Cox proportional regression models were built to identify variables impacting overall survival. Statistical tests were two-sided. Tumors were considered to harbor active TAZ/YAP-driven gene transcription when they co-expressed TAZ, or YAP, and CTGF. Patients whose tumors had the TAZ/CTGF and YAP/CTGF phenotypes experienced shorter overall survival compared with their negative counterparts (log rank p = 0.036 for both). TAZ/CTGF and YAP/CTGF tumors were associated with decreased survival in patients with invasive ductal carcinomas, G3 tumors, hormone receptor-positive tumors, and tumors with elevated Ki-67. Multivariate analyses confirmed that the TAZ/CTGF and YAP/CTGF phenotypes are independent predictors of survival (HR 2.03, 95% CI: 1.06-3.90, p = 0.033; and HR 2.00, 95% CI: 1.04-3.84, p = 0.037 respectively). Comparable results were obtained when excluding uncommon histotypes (TAZ/CTGF: HR 2.34, 95% CI: 1.16-4.73, p = 0.018. YAP/CTGF: HR 2.36, 95% CI: 1.17-4.77, p = 0.017). Overall, the TAZ/YAP-driven oncogenic program may be active in MBC, conferring poorer survival.

Original languageEnglish
Pages (from-to)43188-43198
Number of pages11
JournalOncotarget
Volume7
Issue number28
DOIs
Publication statusPublished - 2016

Keywords

  • Hippo pathway
  • Hippo transducers
  • Male breast cancer
  • TAZ
  • YAP

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Di Benedetto, A., Mottolese, M., Sperati, F., Ercolani, C., Di Lauro, L., Pizzuti, L., Vici, P., Terrenato, I., Sperduti, I., Shaaban, A. M., Sundara-Rajan, S., Barba, M., Speirs, V., De Maria, R., & Maugeri-Saccà, M. (2016). The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer. Oncotarget, 7(28), 43188-43198. https://doi.org/10.18632/oncotarget.9668